About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
AGN - Allergan plc.| Previous Close | $193.02 | Open | |
| Volume | Market Cap | 63.364B | |
| Yield | 1.53 % | Last Dividend | $2.96 |
| AbbVie Inc. Completes Acquisition of All... | 05/08/20 |
| DUBLIN, May 8, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO S... | |
| COVID-19 Impact and Recovery Analysis- G... | 05/08/20 |
| LONDON--(BUSINESS WIRE)-- #ChemicalPeelMarket--The chemical peel market is poised to grow by 62.78 mn during 2020-2024, according to Technavio | |
| The Allergan Foundation Doubles its COVI... | 05/07/20 |
| DUBLIN, May 7, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that The Allergan Foundation has fast-tracked another $2 million dollars ... | |
| Is Aegon NV (AEG) Stock Undervalued Righ... | 05/06/20 |
| Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Neverthe... | |
| Announcement relating to the outcome of ... | 05/06/20 |
| DUBLIN, May 6, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO S... | |
| AbbVie Scores US Antitrust Approval for ... | 05/06/20 |
| AbbVie???s (ABBV) plan to close the $63 billion Allergan (AGN) deal this month appears on track following the announcement that they have received ???... | |
| COVID-19 favors AbbVie (ABBV) in reporti... | 05/04/20 |
| AbbVie, which is expecting to close the acquisition of Allergan in this month, reported its first quarter 2020 earnings results last Friday. The drug ... | |
| United States Hyaluronic Acid-Based Derm... | 04/29/20 |
| DUBLIN--(BUSINESS WIRE)--The "US Hyaluronic Acid-Based Dermal Fillers Market 2025" report has been added to ResearchAndMarkets.com's offering. The US ... | |
| Announcement relating to the voluntary d... | 04/28/20 |
| DUBLIN, April 28, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO D... | |
| Ironwood and Allergan Receive Notices of... | 04/28/20 |
| BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the United States Patent and Trademark Office (USPTO) has ... | |
| You May Want to Slow Down on Allergan St... | 04/28/20 |
| Before the novel coronavirus changed everything, AbbVie???s buyout of Allergan stock made sense. Now, it???s a big question mark. | |
| 2020 Depression Pipeline Landscape Insig... | 04/27/20 |
| DUBLIN , April 27, 2020 /PRNewswire/ -- The "Depression - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering... | |
| An money-management duo overseeing $37 b... | 04/20/20 |
| Dan Davidowitz ??? the lead portfolio manager of the focus growth strategy at Polen Capital ??? and Jeff Mueller ??? co-portfolio manager of the globa... | |
| Pre & Post COVID-19 Market Estimates-Glo... | 04/20/20 |
| LONDON--(BUSINESS WIRE)-- #PruritusTherapeuticMarket--The pruritus therapeutic market size has the potential to grow by USD 3.63 billion during 2020-2... | |
| The World Market for Geriatric Medicines... | 04/17/20 |
| DUBLIN, April 17, 2020 /PRNewswire/ -- The "Geriatric Medicines Market - Growth, Trends, and Forecast (2020-2025)" report has been added to ResearchAn... | |
| Insights on the Worldwide Optic Nerve Di... | 04/14/20 |
| DUBLIN--(BUSINESS WIRE)--The "Optic Nerve Disorders Treatment Market, and Surgery - Global Industry Analysis, Size, Share, Growth, Trends, and Forecas... | |
| Worldwide Aesthetic Lasers and Energy De... | 04/14/20 |
| DUBLIN--(BUSINESS WIRE)--The "Aesthetic Lasers and Energy Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2... | |
| ALLERGAN PLC : Stock Market News and Inf... | 04/14/20 |
| ALLERGAN PLC : News, information and stories for ALLERGAN PLC | Nyse: AGN | Nyse | |
| Addiction Treatment Market ??? A compreh... | 04/10/20 |
| Get a view on global Addiction Treatment market sales by marketing channels. Target important market by region and tap important dynamics of this indu... | |
| Allergan : Form 8.3 - -2- | MarketScreen... | 03/24/20 |
| ----------------------------------------------------------- N/A ----------------------------------------------------------- Is a Supplemental Form 8 a... | |
| The Daily Biotech Pulse: AbbVie, Allerga... | 03/18/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17)... | |
| AbbVie and Allergan ink agreement with F... | 03/17/20 |
| Moving closer to the finish line of their planned merger, AbbVie (NYSE:ABBV) and Allergan (NYSE:AGN) have inked a consent decree agreement with the U.... | |
| AbbVie and Allergan Sign Consent Decree ... | 03/17/20 |
| /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical ... | |
| Allergan (AGN) Down 5.9% Since Last Earn... | 03/11/20 |
| Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Allergan's (AGN) Glaucoma Implant Duryst... | 03/06/20 |
| Allergan's (AGN) Durysta (bimatoprost) gets FDA approval to reduce intraocular pressure in patients with open-angle glaucoma. | |
| Editas, Allergan Start Dosing in Early-S... | 03/05/20 |
| Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited fo... | |
| London Stock Exchange : Form 38.5 (b) - ... | 03/05/20 |
| Allergan Plc Released 11:03 05-Mar-2020 ??? | |
| London Stock Exchange : Form 38.5(a) - A... | 03/04/20 |
| Allergan PLC Released 11:52 04-Mar-2020 ??? | |
| Allergan to pay $51 mln to resolve Resta... | 02/26/20 |
| Allergan PLC has agreed to pay nearly $51.3 million to resolve allegations that the drugmaker violated antitrust laws by improperly trying to delay U.... | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
